Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH

Current Problems in Cancer

Volumn 41, Issue 3, 2017, Pages 182-193

  Coyne, Geraldine O'Sullivan ^a   Takebe, Naoko ^a   Chen, Alice P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Actionable mutation; Anticancer; Precision medicine

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; AFATINIB; ANTINEOPLASTIC AGENT; AZD 4547; BINIMETINIB; BIOLOGICAL MARKER; CRIZOTINIB; DABRAFENIB; DASATINIB; DEFACTINIB; EVEROLIMUS; GSK 2636771; NIVOLUMAB; OSIMERTINIB; PALBOCICLIB; SUNITINIB; TASELISIB; TRAMETINIB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VELIPARIB; VEMURAFENIB; VISMODEGIB;

ARTICLE; CANCER SURVIVAL; CLINICAL OUTCOME; DATA ANALYSIS; DRUG EFFICACY; GENE MUTATION; GENOTYPE; HUMAN; NATIONAL HEALTH ORGANIZATION; NEXT GENERATION SEQUENCING; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGRESSION FREE SURVIVAL; PUBLIC-PRIVATE PARTNERSHIP; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID MALIGNANT NEOPLASM; STUDY DESIGN; TUMOR BIOPSY; CLINICAL TRIAL (TOPIC); GENE EXPRESSION PROFILING; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; INTERSECTORAL COLLABORATION; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; PATHOLOGY; PROCEDURES; TRENDS; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTERSECTORAL COLLABORATION; MOLECULAR TARGETED THERAPY; MUTATION; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PRECISION MEDICINE; UNITED STATES;

EID: 85016473902     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2017.02.001     Document Type: Article

References (41)

1. DeVita, V.T. Jr, Chu, E., A history of cancer chemotherapy. Cancer Res. 68:21 (2008), 8643–8653.
2. Pao, W., Miller, V., Zakowski, M., et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:36 (2004), 13306–13311.
3. Kazandjian, D., Blumenthal, G.M., Chen, H.Y., et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 19:10 (2014), e5–e11.
4. Chapman, P.B., Hauschild, A., Robert, C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:26 (2011), 2507–2516.
5. Hauschild, A., Grob, J.J., Demidov, L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380:9839 (2012), 358–365.
6. Fountzilas, G., Bobos, M., Kalogera-Fountzila, A., et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer investigation. 26:8 (2008), 784–793 Epub 2008/09/18.
7. Kopetz, S., Desai, J., Chan, E., et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 33:34 (2015), 4032–4038.
8. Kummar, S., Williams, P.M., Lih, C.-J., et al. Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers. JNCI: J Natl Cancer Inst, 107(4), 2015.
9. Lin, J.J., Shaw, A.T., Resisting Resistance: Targeted Therapies in Lung Cancer. Trends in Cancer 2:7 (2016), 350–364.
10. Dy, G.K., Adjei, A.A., Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA: A Cancer Journal for Clinicians 63:4 (2013), 249–279.
11. Carr, T.H., McEwen, R., Dougherty, B., et al. Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer 16:5 (2016), 319–329.
12. Schwaederle, M., Parker, B.A., Schwab, R.B., et al. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther 15:4 (2016), 743–752.
13. Institute NC. NCI and the Precision Medicine Initiative, 2017 Available from: https://www.cancer.gov/research/key-initiatives/precision-medicine.
14. Division of Cancer Treatment and Diagnosis (DCTD) at the National Cancer Institute. NCI-Sponsored trials in Precision Medicine [updated 01/26/2017; cited 2017 January 2017]. Available from: http://dctd.cancer.gov/MajorInitiatives/NCI-sponsored_trials_in_precision_medicine.htm.
15. Do, K., O'Sullivan Coyne, G., Chen, A.P., An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol, 4(3), 2015, 31.
16. van der Graaf, W.T.A., Blay, J-Y, Chawla, S.P., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 379:9829 (2012), 1879–1886.
17. Zhao, Y., Polley, E.C., Li, M.C., et al. GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials. Cancer informatics. 14:Suppl 2 (2015), 45–55 Epub 2015/04/11.
18. Forbes, S.A., Beare, D., Gunasekaran, P., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Research 43:D1 (2014), D805–D811.
19. Forbes, S.A., Bindal, N., Bamford, S., et al., COSMIC. mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Research 39:suppl_1 (2010), D945–D950.
20. Lih, C.J., Sims, D.J., Harrington, R.D., et al. Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. J Mol Diagn 18:1 (2016), 51–67.
21. Yamaguchi, T., Kakefuda, R., Tajima, N., et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. International Journal of Oncology 39:1 (2011), 23–31.
22. Grünwald, V., Karakiewicz, P.I., Bavbek, S.E., et al. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer 48:3 (2012), 324–332.
23. Motzer, R.J., Escudier, B., Oudard, S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet 372:9637 (2008), 449–456.
24. Palma, J.P., Wang, Y.-C., Rodriguez, L.E., et al. ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors. Clinical Cancer Research 15:23 (2009), 7277–7290.
25. Kummar, S., Williams, M., Lih, C.J., et al. NCI-MPACT: National Cancer Institute molecular profiling-based assignment of therapy. 2014 American Society of Clinical Cancer Annual Meeting. J Clin Oncol, 32, 2014 5s, 2014 (suppl; abstr TPS2642).
26. Conley, B.A., Flaherty, Keith, T., Molecular Analysis for Therapy Choice (NCI-MATCH): A Precision Medicine Signal-Seeking Trial in Oncology. Personalized Medicine in Oncology [Internet], 2016 January 2017; 5. Available from: http://www.personalizedmedonc.com/publications/pmo/october-2016-vol-5-no-8/molecular-analysis-for-therapy-choice-nci-match/.
27. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:2 (2009), 228–247.
28. Cheson, B.D., Fisher, R.I., Barrington, S.F., et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:27 (2014), 3059–3068.
29. Wen, P.Y., Macdonald, D.R., Reardon, D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:11 (2010), 1963–1972.
30. Cancer Genome Atlas Research, N., Weinstein, J.N., Collisson, E.A., et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 45:10 (2013), 1113–1120.
31. Cerami, E., Gao, J., Dogrusoz, U., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:5 (2012), 401–404.
32. My Cancer Genome [updated 2017; cited 2017 January 2017]. Available from: https://www.mycancergenome.org/.
33. Chen A, Conley B. Hamilton S. et al. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public–private partnership. 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Abstract 418. EORTC-NCI-AACR Symptosium on Molecular Targets and Cancer Therapeutics; 2016; European Journal of Cancer: Abstract Book.
34. Catenacci, D.V.T., Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Molecular Oncology 9:5 (2015), 967–996.
35. McNeil, C., NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era. JNCI: Journal of the National Cancer Institute, 107(7), 2015 djv193-djv193.
36. Palmisano, A., Zhao, Y., Li, M.C., et al. OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials. Brief Bioinform., 2016.
37. Le Tourneau, C., Delord, J.P., Goncalves, A., et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16:13 (2015), 1324–1334.
38. Stockley, T.L., Oza, A.M., Berman, H.K., et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med., 8(1), 2016, 109.
39. Swanton, C., Intratumor Heterogeneity: Evolution through Space and Time. Cancer Research. 72:19 (2012), 4875–4882.
40. Tannock, I.F., Hickman, J.A., Limits to Personalized Cancer Medicine. New England Journal of Medicine 375:13 (2016), 1289–1294.
41. Kern, K.A., Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology. Journal of Oncology Practice 12:8 (2016), e810–e817.